剥离收入规模近28亿美元的糖尿病业务,对于美敦力只是“洒洒水”

Ofweek维科网
23 May

美敦力一刀先“砍”向糖尿病业务。来源|医药研究社全球“器械一哥”也在“断舍离”。5月21日,美敦力宣布将其糖尿病业务分拆为一家全新的独立公司,此次分拆预计将在18个月内通过一系列资本市场交易完成,优先考虑采用首次公开募股(IPO)及后续股权剥离的方式。此前,美敦力也宣布了最新人事任命,如任命Dexcom前高管Laura Endres为糖尿病业务美洲区负责人、任命Kate Cronin担任糖尿病业务...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10